Page 647 - Read Online

Adler et al. J Cancer Metastasis Treat 2019;5:45 I http://dx.doi.org/10.20517/2394-4722.2019.03 Page 11 of 12

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. AWMF online. Available from: https://www.awmf.org/uploads/tx_szleitlinien/032-045OLl_S3_Mammakarzinom_2018-09.pdf. [Last
accessed on 25 Apr 2019]
2. Bollen L, Wibmer C, Wang M, van der Linden YM, Leithner A, et al. Molecular phenotype is associated with survival in breast cancer
patients with spinal bone metastases. Clin Exp Metastasis 2015;32:1-5.
3. Wang M, Jensen AB, Morgen SS, Wu CS, Sun M, et al. Survival analysis of breast cancer subtypes in patients with spinal metastases.
Spine (Phila Pa 1976) 2014;39:1620-7.
4. Cardoso F, Costa A, Senkus E, Aapro M, André F, et al. 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC
3). Ann Oncol 2017;28:3111.
5. Elkablawy MA, Albasri AM, Mohammed RA. Ki67 expression in breast cancer. Correlation with prognostic markers and
clinicopathological parameters in Saudi patients. Saudi Med J 2016;37:137-41.
6. Feeley LP, Mulligan AM, Pinnaduwage D. Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status
provides prognostic information. Mod Pathol 2014;27:554-61.
7. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, et al. Strategies for subtypes dealing with the diversity of breast cancer:
highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011;22:1736-
47.
8. Harbeck N. Breast cancer: tumor biology-based concepts for surgical and drug treatment. Dtsch Med Wochenschr 2013;138:180-2. (in
German)
9. Jiehua Li, Zhibai Chen, Ka Su, Jian Zeng. Clinicopathological classification and traditional prognostic indicators of breast cancer. Int J
Clin Exp Pathol 2015;8:8500-5.
10. Kobayashi K, Ito Y, Matsuura M, Fukada I, Horii R, et al. Impact of immunohistological subtypes on the long-term prognosis of patients
with metastatic breast cancer. Surg Today 2016;46:821-6.
11. Putzier M, Haschke F. Diagnostic standards for extradural tumors and metastases of the spinal column. Orthopäde 2013;42:691-9. (in
German)
12. Sciubba DM, Gokaslan ZL, Suk I, Suki D, Maldaun MV, et al. Positive and negative prognostic variables for patients undergoing spine
surgery for metastatic breast disease. Eur Spine J 2007;16:1659-67.
13. Sciubba DM, Goodwin CR, Yurter A, Ju D, Ziya LG, et al. A systematic review of clinical outcomes and prognostic factors for patients
undergoing surgery for spinal metastases secondary to breast cancer. Global Spine J 2016;6:482-96.
14. Sorlie T, Perou CM, Tibshirani R, Geisler S, Johnson H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses
with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
15. Tang P, Tse GM. Immunohistochemical surrogates for molecular classification of breast carcinoma: a 2015 update. Arch Pathol Lab Med
2016;140:806-14.
16. Bauer HC, Wedin R. Survival after surgery for spinal and extremity metastases. Prognostication in 241 patients. Acta Orthop Scand
1995;66:143-6.
17. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. MacLeod CM (Ed), Evaluation of
Chemotherapeutic Agents. Columbia Univ Press 1949;191-205.
18. Tokuhashi Y, Matsuzaki H, Oda H, Oshima M, Ryu J. A revised scoring system for preoperative evaluation of metastatic spine tumor
prognosis. Spine (Phila Pa 1976) 2005;30:2186-91.
19. Tomita K, Kawahara N, Kobayashi T, Yoshida A, Murakami H, et al. Surgical strategy for spinal metastases. Spine (Phila Pa 1976)
2001;26:298-306.
20. Van der Linden YM, Dijkstra SPDS, Vonk EJ, Marijnen CA, Leer JW. Prediction of survival in patients with metastases in the spinal
column: results based on a randomized trial of radiotherapy. Cancer 2005;103:320-8.
21. Von der Höh NH, Gulow J, Tschöke SK, Völker A, Heyde CE. Prognosis scores for spinal metastases. Orthopäde 2013;42:725-33.
22. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
23. Bastien RR, Rodríguez-Lescure Á, Ebbert MT, Prat A, Munárriz B, et al. PAM50 breast cancer subtyping by RT-qPCR and concordance
with standard clinical molecular markers. BMC Med Genomics 2012;5:44.
24. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, et al. Subtyping of breast cancer by immunohistochemistry to
investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12
studies. PLoS Med 2010;7:e1000279.
25. Coleman R, Powles T, Paterson A. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data
from randomised trials. Lancet 2015;386:1353-61.
26. Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of
adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011;378:771-84.
27. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, et al. Recommendations for human epidermal growth factor receptor 2